Pub Date : 2020-01-20DOI: 10.46624/ajphr.2020.v8.i1.006
N. Iqbal, B. D. Khan
{"title":"Mother and Child Wellbeing In Unani System Of Medicine","authors":"N. Iqbal, B. D. Khan","doi":"10.46624/ajphr.2020.v8.i1.006","DOIUrl":"https://doi.org/10.46624/ajphr.2020.v8.i1.006","url":null,"abstract":"","PeriodicalId":7701,"journal":{"name":"American Journal of PharmTech Research","volume":"44 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74060006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-20DOI: 10.46624/ajphr.2020.v8.i1.005
A. Perveen, N. Jahan, Tanwir Alam, S. Perveen
One of the most powerful relationships is in between a mother’s health and her child’s overall development. Throughout the world, especially in the developing countries, there is an increasing concern and interest in maternal and child health care. Woman is major determinant for her family’s development and indirectly to a nation so higher priority should be laid on policies for woman and child health. Unani can help improving Mother and Child Health (MCH) through increased access to low cost high quality healthcare, free from undesirable side-effects. This article emphasizes the Unani ways to conserve and maintain MCH so as to provide a healthy environment to upcoming generation. It highlights the potentials of Unani medicine and suggests ways to adopt these practices.
{"title":"Mother and Child Wellbeing In Unani System Of Medicine","authors":"A. Perveen, N. Jahan, Tanwir Alam, S. Perveen","doi":"10.46624/ajphr.2020.v8.i1.005","DOIUrl":"https://doi.org/10.46624/ajphr.2020.v8.i1.005","url":null,"abstract":"One of the most powerful relationships is in between a mother’s health and her child’s overall development. Throughout the world, especially in the developing countries, there is an increasing concern and interest in maternal and child health care. Woman is major determinant for her family’s development and indirectly to a nation so higher priority should be laid on policies for woman and child health. Unani can help improving Mother and Child Health (MCH) through increased access to low cost high quality healthcare, free from undesirable side-effects. This article emphasizes the Unani ways to conserve and maintain MCH so as to provide a healthy environment to upcoming generation. It highlights the potentials of Unani medicine and suggests ways to adopt these practices.","PeriodicalId":7701,"journal":{"name":"American Journal of PharmTech Research","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88435161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-08DOI: 10.46624/ajptr.2019.v9.i5.010
S. Swaminathan, R. Elanthendral
Researches done on the use of statins during the last two decades have shown conflicting results in their effects on DM, Cardiac, liver and Kidney functions. Six forms of statins are being prescribed as a preventive measure to reduce the incidence of cardiovascular morbidity and mortality; but statin use have also shown alternations in DM, liver and Kidney function. The latest observations relates to cancer prevention/induction. Statins prescriptions are done mostly for elderly patients in order to reduce lipid profile mostly Total cholesterol and LDL levels. Studies have shown that statins use affects muscular function, induce prediabetes, and alter liver enzymes and affects mitochondrial functions. They may also interact with other medications. Some merits shown in the use of statins include prevention of MCI and strokes. Among the statins used, atorvastatin was found to be very beneficial with minimal side effects with greater beneficial function in maintaining other organ functions. This review article highlights the research findings on the use of statins and its merits and demerits during the last two decades. More clinical trials with large population are required to establish the type of statins to be required for each type of patients and clinical conditions.
{"title":"Effect of Statins use on Cardiac, Diabetes, Kidney and Liver Function – An update","authors":"S. Swaminathan, R. Elanthendral","doi":"10.46624/ajptr.2019.v9.i5.010","DOIUrl":"https://doi.org/10.46624/ajptr.2019.v9.i5.010","url":null,"abstract":"Researches done on the use of statins during the last two decades have shown conflicting results in their effects on DM, Cardiac, liver and Kidney functions. Six forms of statins are being prescribed as a preventive measure to reduce the incidence of cardiovascular morbidity and mortality; but statin use have also shown alternations in DM, liver and Kidney function. The latest observations relates to cancer prevention/induction. Statins prescriptions are done mostly for elderly patients in order to reduce lipid profile mostly Total cholesterol and LDL levels. Studies have shown that statins use affects muscular function, induce prediabetes, and alter liver enzymes and affects mitochondrial functions. They may also interact with other medications. Some merits shown in the use of statins include prevention of MCI and strokes. Among the statins used, atorvastatin was found to be very beneficial with minimal side effects with greater beneficial function in maintaining other organ functions. This review article highlights the research findings on the use of statins and its merits and demerits during the last two decades. More clinical trials with large population are required to establish the type of statins to be required for each type of patients and clinical conditions.","PeriodicalId":7701,"journal":{"name":"American Journal of PharmTech Research","volume":"1964 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91344404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-08DOI: 10.46624/ajptr.2019.v9.i5.009
Alisha Ishrath, Venkataratnam Devadas, M. M. Ahmed
Please cite this article as: Ishrath A et al., Formulation Development and Characterization of Diltiazem Pulsin Cap for Pulsatile Drug Delivery . American Journal of PharmTech Research 2019. Formulation Development and Characterization of Diltiazem Pulsin Cap for Pulsatile Drug Delivery Alisha Ishrath, Venkataratnam Devadas, Mohammed Mazher Ahmed 1.Department of Pharmaceutics, MAK College of Pharmacy, Hyderabad, Telangana, India 2.Department of Pharmaceutics, Luqman College of Pharmacy, Gulbarga, Karnataka, India ABSTRACT The aim of this work is to develop modified drug release by using Pulsin Cap technique with Diltiazem as model drug. From the above experimental results, it can be concluded that, Formulated granules gave satisfactory results for various micromeritic properties, dissolution and drug content. Formulated Pulsin Cap gave satisfactory results for various physicochemical parameters like weight variation. HPMC, Ethyl cellulose has predominant effect on the lag time, while also shows significant effect on drug release. Diltiazem Pulsin Cap shows a delayed release pattern. Among all the Diltiazem granules formulations F5 was selected based on drug release within a given period of time. In-vitro release rate studies showed that the PF5 was optimized based on less amount of drug release during lag time. Formulations PF5 found to be stable at 40 C and 75% RH for a period of 3 months. FT-IR studies revealed that there was no interaction between Diltiazem and the polymers.
{"title":"Formulation Development and Characterization of Diltiazem Pulsin Cap for Pulsatile Drug Delivery","authors":"Alisha Ishrath, Venkataratnam Devadas, M. M. Ahmed","doi":"10.46624/ajptr.2019.v9.i5.009","DOIUrl":"https://doi.org/10.46624/ajptr.2019.v9.i5.009","url":null,"abstract":"Please cite this article as: Ishrath A et al., Formulation Development and Characterization of Diltiazem Pulsin Cap for Pulsatile Drug Delivery . American Journal of PharmTech Research 2019. Formulation Development and Characterization of Diltiazem Pulsin Cap for Pulsatile Drug Delivery Alisha Ishrath, Venkataratnam Devadas, Mohammed Mazher Ahmed 1.Department of Pharmaceutics, MAK College of Pharmacy, Hyderabad, Telangana, India 2.Department of Pharmaceutics, Luqman College of Pharmacy, Gulbarga, Karnataka, India ABSTRACT The aim of this work is to develop modified drug release by using Pulsin Cap technique with Diltiazem as model drug. From the above experimental results, it can be concluded that, Formulated granules gave satisfactory results for various micromeritic properties, dissolution and drug content. Formulated Pulsin Cap gave satisfactory results for various physicochemical parameters like weight variation. HPMC, Ethyl cellulose has predominant effect on the lag time, while also shows significant effect on drug release. Diltiazem Pulsin Cap shows a delayed release pattern. Among all the Diltiazem granules formulations F5 was selected based on drug release within a given period of time. In-vitro release rate studies showed that the PF5 was optimized based on less amount of drug release during lag time. Formulations PF5 found to be stable at 40 C and 75% RH for a period of 3 months. FT-IR studies revealed that there was no interaction between Diltiazem and the polymers.","PeriodicalId":7701,"journal":{"name":"American Journal of PharmTech Research","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72833333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-08DOI: 10.46624/ajptr.2019.v9.i5.019
O. D, Davaasuren Ts, E. B, D. D, Jambaninj D
Please cite this article as: Jambaninj D et al., Study on drug release and stability of matrix tablet contained monoammonium glycyrrhizinate. American Journal of PharmTech Research 2019. Study on drug release and stability of matrix tablet contained monoammonium glycyrrhizinate Otgonsuren.D, Davaasuren.Ts,Enkhtuul.B, Davaadagva.D, Jambaninj.D 1.Department of pharaceutical technology, School of Pharmacy, Mongolian National University of Medical Sciences ABSTRACT Monoammonium glycyrrhizinate was determined it has anti-viral activity in case of hepatitis A, B, C, D. We have developed matrix tablet contained monoammonium glycyrrhizinate by previous study. The objective of the study was to evaluate drug release of matrix tablet in vivo and determinate its stability. In the present study was evaluated in vivo drug release of the matrix tablet. Stability testing was 230 determinated by long term and accelerated method by such criteria’s: appearance, weight variation, biological active compound, hardness, friability, dissolution and microbiological contamination. The Cmax (μg/ml), Tmax (h), AUC0-t (μg h/ml) of Glycyron tablet and Licozinat matrix tablet were determined in vivo. Stability of the matrix tablet was determined. Licozinat matrix tablet was released drug by prolonged time by in vitro. In vivo pharmacokinetic study in rabbits confirmed the prolonged release by showing increase in bioavailability for matrix tablet compared to Glycyron tablet. Licozinat matrix tablet was stable for 12 months. Stability testing of matrix tablet is continuing by long term method.
{"title":"Study on drug release and stability of matrix tablet contained monoammonium glycyrrhizinate","authors":"O. D, Davaasuren Ts, E. B, D. D, Jambaninj D","doi":"10.46624/ajptr.2019.v9.i5.019","DOIUrl":"https://doi.org/10.46624/ajptr.2019.v9.i5.019","url":null,"abstract":"Please cite this article as: Jambaninj D et al., Study on drug release and stability of matrix tablet contained monoammonium glycyrrhizinate. American Journal of PharmTech Research 2019. Study on drug release and stability of matrix tablet contained monoammonium glycyrrhizinate Otgonsuren.D, Davaasuren.Ts,Enkhtuul.B, Davaadagva.D, Jambaninj.D 1.Department of pharaceutical technology, School of Pharmacy, Mongolian National University of Medical Sciences ABSTRACT Monoammonium glycyrrhizinate was determined it has anti-viral activity in case of hepatitis A, B, C, D. We have developed matrix tablet contained monoammonium glycyrrhizinate by previous study. The objective of the study was to evaluate drug release of matrix tablet in vivo and determinate its stability. In the present study was evaluated in vivo drug release of the matrix tablet. Stability testing was 230 determinated by long term and accelerated method by such criteria’s: appearance, weight variation, biological active compound, hardness, friability, dissolution and microbiological contamination. The Cmax (μg/ml), Tmax (h), AUC0-t (μg h/ml) of Glycyron tablet and Licozinat matrix tablet were determined in vivo. Stability of the matrix tablet was determined. Licozinat matrix tablet was released drug by prolonged time by in vitro. In vivo pharmacokinetic study in rabbits confirmed the prolonged release by showing increase in bioavailability for matrix tablet compared to Glycyron tablet. Licozinat matrix tablet was stable for 12 months. Stability testing of matrix tablet is continuing by long term method.","PeriodicalId":7701,"journal":{"name":"American Journal of PharmTech Research","volume":"55 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77073068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-08DOI: 10.46624/ajptr.2019.v9.i5.017
Hunashal Sarah Priya, B. Patil, Ravindra S. Jeevanagi
Candesartan cilexetil is a prodrug of candesartan – a compound that inhibits binding of angiotensin II to the AT1 – receptor. It is mainly used in the treatment of hypertension. In the present work attempts were mase to prepare fast dissolving tablets of candesartan cilexetil by sublimation technique. The prepared formulations were evaluated for pre-compressional and postcompressional parameters. The compatibility of drug with other ingredients was checked by FTIR studies, these results revealed that there was no interaction between dug and other excipients. The values of pre-compressional parameters were within prescribed limits and indicated good free flowing properties. In all the formulations the hardness test indicates good mechanical strength. Friability of all formulations was less than 1. Drug content was found to be high (≥ 100.27%) and uniform in all the formulations. The tablet thickness was found to be 3.14 – 3.47. The weight variation results revealed that average percentage deviation was less then ± 7.5 %, which provides good uniformity in all formulations. The disintegration time of the tablets decreased significantly with increase in the concentration of subliming agent. The formulations CSC3, CSM3, CSA3, and CSU3 50 % of drug released in 1.38, 2.55, 4.00 and 3.57 min, and 90 % of drug released in 3.39, 6.04, 7.50 and 7.18 min. The formulation CS (control) released 42.16 % in 60 min. Stability study carried out as per ICH guidelines for three months and results revealed that upon storage disintegration time of tablets decreased significantly (p<0.05). The results concluded that by adopting a systemic formulation approach, an optimum point could be reached in the shortest time with minimum efforts. Sublimation technique would be an effective alternative approach compared with the use of more expensive adjuvants in the formulations of fast dissolving tablets.
{"title":"Formulation and Development of Candesartan Cilexetil Fast Dissolving Tablets by Sublimation Technique","authors":"Hunashal Sarah Priya, B. Patil, Ravindra S. Jeevanagi","doi":"10.46624/ajptr.2019.v9.i5.017","DOIUrl":"https://doi.org/10.46624/ajptr.2019.v9.i5.017","url":null,"abstract":"Candesartan cilexetil is a prodrug of candesartan – a compound that inhibits binding of angiotensin II to the AT1 – receptor. It is mainly used in the treatment of hypertension. In the present work attempts were mase to prepare fast dissolving tablets of candesartan cilexetil by sublimation technique. The prepared formulations were evaluated for pre-compressional and postcompressional parameters. The compatibility of drug with other ingredients was checked by FTIR studies, these results revealed that there was no interaction between dug and other excipients. The values of pre-compressional parameters were within prescribed limits and indicated good free flowing properties. In all the formulations the hardness test indicates good mechanical strength. Friability of all formulations was less than 1. Drug content was found to be high (≥ 100.27%) and uniform in all the formulations. The tablet thickness was found to be 3.14 – 3.47. The weight variation results revealed that average percentage deviation was less then ± 7.5 %, which provides good uniformity in all formulations. The disintegration time of the tablets decreased significantly with increase in the concentration of subliming agent. The formulations CSC3, CSM3, CSA3, and CSU3 50 % of drug released in 1.38, 2.55, 4.00 and 3.57 min, and 90 % of drug released in 3.39, 6.04, 7.50 and 7.18 min. The formulation CS (control) released 42.16 % in 60 min. Stability study carried out as per ICH guidelines for three months and results revealed that upon storage disintegration time of tablets decreased significantly (p<0.05). The results concluded that by adopting a systemic formulation approach, an optimum point could be reached in the shortest time with minimum efforts. Sublimation technique would be an effective alternative approach compared with the use of more expensive adjuvants in the formulations of fast dissolving tablets.","PeriodicalId":7701,"journal":{"name":"American Journal of PharmTech Research","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81254394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-08DOI: 10.46624/ajptr.2019.v9.i5.013
P. Tripura sundari, Ch. Sai Akshitha
{"title":"Formulation and Evaluation of Escitalopram Nanoparticles by Employing Cutina As Lipid","authors":"P. Tripura sundari, Ch. Sai Akshitha","doi":"10.46624/ajptr.2019.v9.i5.013","DOIUrl":"https://doi.org/10.46624/ajptr.2019.v9.i5.013","url":null,"abstract":"","PeriodicalId":7701,"journal":{"name":"American Journal of PharmTech Research","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90631948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-08DOI: 10.46624/ajptr.2019.v9.i5.008
V. Chavan, Kundan J., Tiwari Kiran, A. Suryavanshi, Aditya S. Bhor
The aimed to formulate and evaluate herbal shampoo because synthetic may causes the adverse effect on hair and scalp. The herbal shampoo was formulated by extracting murraya koenigi, sapindusmukorossias foaming agent, also addition of preservative agent. Citric acid used as viscosity modifier and pH adjusting agent and glycerin used as conditioning agent. HPMC(hydroxyl propyl methyl cellulose) used as thickening agent. The formulation at laboratory scale was done and evaluated for number of parameters such as pH, foam formation, viscosity, conditioning and wet ability were evaluated, and also to ensure its safety and efficacy
{"title":"Formulation and Evaluation of Herbal Shampoo","authors":"V. Chavan, Kundan J., Tiwari Kiran, A. Suryavanshi, Aditya S. Bhor","doi":"10.46624/ajptr.2019.v9.i5.008","DOIUrl":"https://doi.org/10.46624/ajptr.2019.v9.i5.008","url":null,"abstract":"The aimed to formulate and evaluate herbal shampoo because synthetic may causes the adverse effect on hair and scalp. The herbal shampoo was formulated by extracting murraya koenigi, sapindusmukorossias foaming agent, also addition of preservative agent. Citric acid used as viscosity modifier and pH adjusting agent and glycerin used as conditioning agent. HPMC(hydroxyl propyl methyl cellulose) used as thickening agent. The formulation at laboratory scale was done and evaluated for number of parameters such as pH, foam formation, viscosity, conditioning and wet ability were evaluated, and also to ensure its safety and efficacy","PeriodicalId":7701,"journal":{"name":"American Journal of PharmTech Research","volume":"102 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80498974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-08DOI: 10.46624/ajptr.2019.v9.i5.016
S. Avutu, Shaheem Sulthana Mohammad, Jhansi Lakshmi Marreddy
Please cite this article as: Avutu SL et al., Clinico-Epidemiological Study of HIV-TB Co-Infection In Southern Indias. American Journal of PharmTech Research 2019. Clinico-Epidemiological Study of HIV-TB Co-Infection In Southern India Sri Lakshmi Avutu*, Shaheem Sulthana Mohammad, Jhansi Lakshmi Marreddy 1.Department of Pharmacology, ASN Pharmacy College, Burripalem Road, Tenali-522201, Andhra Pradesh, India. 2.Department of Pharmaceutical Analysis & Quality Assurance, ASN Pharmacy College, Burripalem Road, Tenali-522201, Andhra Pradesh, India. 3.Department of Pharmaceutical Analysis, ASN Pharmacy College, Burripalem Road, Tenali522201, Andhra Pradesh, India. ABSTRACT This study was aimed at identifying the CLINICO-EPIDEMOLOGICAL study of underlying HIV–TB coinfection. A retrospective review of patient records was done from the antiretroviral therapy center (ART) at a government hospital in southern India between June 2018 and April 2019. Secondary data of 10155 patients on ART as well as pre-ART were collected between January 2009 and December 2018 and were analyzed. Wilcoxon signed rank tests were used with SPSS version 15.0 The prevalence of HIV-TB coinfection 0.13% among the sample was taken. HIV–TB coinfection was increased in trend of population from 1.41% in 2009 to 45.3% in 2018 until when the data were included in this study. The proportion of HIV infection among those registering at this particular ART center decreased from 18.7% in 2009 to 6.44% in 2018. The prevalence of HIV infection and HIV-TB coinfection higher in males (3.73% & 33.3%) than females (3.20% & 12.05%) respectively among those registering at this particular ART center. The fatality rate of HIV infection was decreased from 23.4% in 2009 to 2.33% in 2018. The CD4 count (200 cells/μl) lower in co-infected patients than HIV infected patients. The increasing trend of HIV–TB cases observed in this population from 1.41% in 2009 to 45.3% in December 2018. Creating grass root level awareness coupled with aggressive case finding in suspected high-risk population may be key in preventing and early detection of the dual infections.
{"title":"Clinico-Epidemiological Study of HIV-TB Co-Infection In Southern India","authors":"S. Avutu, Shaheem Sulthana Mohammad, Jhansi Lakshmi Marreddy","doi":"10.46624/ajptr.2019.v9.i5.016","DOIUrl":"https://doi.org/10.46624/ajptr.2019.v9.i5.016","url":null,"abstract":"Please cite this article as: Avutu SL et al., Clinico-Epidemiological Study of HIV-TB Co-Infection In Southern Indias. American Journal of PharmTech Research 2019. Clinico-Epidemiological Study of HIV-TB Co-Infection In Southern India Sri Lakshmi Avutu*, Shaheem Sulthana Mohammad, Jhansi Lakshmi Marreddy 1.Department of Pharmacology, ASN Pharmacy College, Burripalem Road, Tenali-522201, Andhra Pradesh, India. 2.Department of Pharmaceutical Analysis & Quality Assurance, ASN Pharmacy College, Burripalem Road, Tenali-522201, Andhra Pradesh, India. 3.Department of Pharmaceutical Analysis, ASN Pharmacy College, Burripalem Road, Tenali522201, Andhra Pradesh, India. ABSTRACT This study was aimed at identifying the CLINICO-EPIDEMOLOGICAL study of underlying HIV–TB coinfection. A retrospective review of patient records was done from the antiretroviral therapy center (ART) at a government hospital in southern India between June 2018 and April 2019. Secondary data of 10155 patients on ART as well as pre-ART were collected between January 2009 and December 2018 and were analyzed. Wilcoxon signed rank tests were used with SPSS version 15.0 The prevalence of HIV-TB coinfection 0.13% among the sample was taken. HIV–TB coinfection was increased in trend of population from 1.41% in 2009 to 45.3% in 2018 until when the data were included in this study. The proportion of HIV infection among those registering at this particular ART center decreased from 18.7% in 2009 to 6.44% in 2018. The prevalence of HIV infection and HIV-TB coinfection higher in males (3.73% & 33.3%) than females (3.20% & 12.05%) respectively among those registering at this particular ART center. The fatality rate of HIV infection was decreased from 23.4% in 2009 to 2.33% in 2018. The CD4 count (200 cells/μl) lower in co-infected patients than HIV infected patients. The increasing trend of HIV–TB cases observed in this population from 1.41% in 2009 to 45.3% in December 2018. Creating grass root level awareness coupled with aggressive case finding in suspected high-risk population may be key in preventing and early detection of the dual infections.","PeriodicalId":7701,"journal":{"name":"American Journal of PharmTech Research","volume":"155 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77475562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-08DOI: 10.46624/ajptr.2019.v9.i5.014
Ch. Sai Akshitha, P. Tripura sundari
{"title":"BioMEM’s As Drug Delivery Systems- A Review","authors":"Ch. Sai Akshitha, P. Tripura sundari","doi":"10.46624/ajptr.2019.v9.i5.014","DOIUrl":"https://doi.org/10.46624/ajptr.2019.v9.i5.014","url":null,"abstract":"","PeriodicalId":7701,"journal":{"name":"American Journal of PharmTech Research","volume":"157 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85378267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：